65,437 trials
Epilepsy
Primary: Number of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study) — 28…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52 — -0.81; -0.76; -0.73 percentage glycosylated hemoglobin
Postoperative Nausea and Vomiting (PONV) · Nausea
Primary: Proportion of Patients With a Complete Response/Complete Control During the First 24 Hours After Neurological Surgery Under General Anesthesia — 38; 41; 30; 30…
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: PFS Rate — 30 percentage of participants
Carcinoma, Renal Cell
Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) — 78; 27 participants
Parkinson's Disease
Primary: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary — -1.24; -1.59 hours — p=0.3257
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) and HPV-18 — 345; 67; 363; 135 Participants
Hyperglycemia · Critical Illness
Primary: All-cause 90-day Mortality — 431; 447 participants
Brainstem Glioma
Primary: Progression-free Survival — 4.9 Months
Lateral Canthus Rhytides · Crow's Feet Lines
Primary: Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile — 25.7; 1.3 Percentage of participants
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Type 2 Diabetes Mellitus
Primary: 24 Hour Weighted Mean Glucose (WMG) At 2 Weeks — 126.9; 114.2 mg/dL
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile — 21.3; 20.6; 0.0 Percentage of participants
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Meningitis · Meningococcal Disease
Primary: Percentage of Participants With Seroconversion Following Vaccination With Either Menactra® or Adacel® Vaccine — 78; 9; 88; 8 Percentage of participants